Skip to main content
ABL Bio Inc. logo

ABL Bio Inc. — Investor Relations & Filings

Ticker · 298380 ISIN · KR7298380007 LEI · 9884007BRC71Y64NK235 KO Professional, scientific and technical activities
Open in API
Filings indexed 369 across all filing types
Latest filing 2026-06-04 Regulatory Filings
Country KR South Korea
Listing KO 298380

About ABL Bio Inc.

https://www.ablbio.com

ABL Bio Inc. is a clinical-stage biotechnology company specializing in the development of bispecific antibody therapeutics for immuno-oncology and neurodegenerative diseases. The company leverages several proprietary platforms. For central nervous system disorders, its 'Grabody-B' technology is a blood-brain barrier (BBB) penetrating shuttle designed to enhance drug delivery to the brain. In immuno-oncology, ABL Bio develops 4-1BB based bispecific antibodies aimed at minimizing toxicity and overcoming resistance to existing immunotherapies. The company is also advancing a pipeline of antibody-drug conjugates (ADCs) with an improved therapeutic index for conditions such as rare blood cancers. ABL Bio actively progresses its therapeutic candidates through clinical development.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(임상시험계획변경승인신청) (이중항체 면역항암제 ABL503의 제1상 임상시험계획 (IND) 변경승인 신청)
Regulatory Filings Classification · 90% confidence The document is a Korean stock exchange disclosure titled “투자판단 관련 주요경영사항” describing a material operational event (clinical trial plan change approval application). It does not contain financial statements or investor presentation slides; instead, it is a routine regulatory announcement of a material corporate event. This fits the general “Regulatory Filings” fallback category (RNS).
2026-06-04 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 100% confidence The document is titled '분기보고서' which translates to 'Quarterly Report' and specifies the period as the first quarter of the 11th fiscal year (2026-01-01 to 2026-03-31). It contains detailed financial data, business overview, risk management, contract details, and other substantive financial and operational information typical of an interim or quarterly report. The length is about 15,000 characters, indicating a full report rather than a brief announcement. There is no indication that this is an announcement of a report or a certification document. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-05-08 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 95% confidence The document is a ‘주식등의 대량보유상황보고서(일반)’, i.e. a large shareholding status report filed under the Capital Markets Act. It details the reporter’s major shareholdings, changes, related parties, and contract information. This matches the ‘Major Shareholding Notification’ category (Code: MRQ).
2026-04-03 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 95% confidence The document is a Korean regulatory form titled “주식등의 대량보유상황보고서(약식)” under the Capital Markets Act. It provides detailed tables of previous and current share counts and ownership percentages, plus change amounts and reasons for a professional investor (National Pension Service). This aligns exactly with a Major Shareholding Notification under category MRQ rather than an earnings release or management report.
2026-04-01 Korean
유상증자결정(종속회사의주요경영사항)
Share Issue/Capital Change Classification · 92% confidence The document is a corporate disclosure titled “유상증자결정(종속회사의 주요경영사항)” detailing the decision to increase capital by issuing new shares (paid‐in capital increase) through a third‐party allotment for a subsidiary. It provides detailed share counts, issue price, purpose of funds, board resolution dates, and subscriber information. This is clearly an announcement of a new share issuance / capital change, fitting the definition of Share Issue/Capital Change (Code: SHA).
2026-03-30 Korean
타법인주식및출자증권취득결정
Capital/Financing Update Classification · 75% confidence The document is a disclosure of the company’s decision to acquire shares and equity securities of another corporation (subsidiary) via participation in a paid-in capital increase. It details the number of shares, acquisition amount, post-transaction ownership and method of acquisition (capital increase participation). This is not an earnings or management report, nor a director dealing or buyback; it is a financing/capital activity update. Therefore it best fits under Capital/Financing Update (CAP).
2026-03-30 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.